Last updated: 11/07/2018 08:04:45
An Active Treatment Study to Induce Clinical Response and/or Remission with GSK1605786A in subjects with Crohn's DiseaseSHIELD-4
EudraCT ID
EU CT Number
Not applicable
Trial status
Other
Other
Trial overview
Official title: A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission with GSK1605786A in Subjects with Moderately-to-Severely Active Crohn’s Disease
Trial description: This is a multi-centre, randomised, double-blind, active treatment, parallel group induction study in subjects with moderately-to-severely active Crohn’s disease. Subjects will receive one of two doses (500 milligrams once daily, 500 milligrams twice daily) of GSK1605786A for 12 weeks. The primary objective of the study is to induce clinical response (Crohn's Disease Activity Index [CDAI] decrease from baseline of at least 100 points) and/or remission (CDAI score less than 150) with GSK1605786A at Week 12 in subjects with active Crohn’s disease to qualify subjects for enrolment into a 52 week maintenance study (CCX114157). Secondary objectives will include assessment of the safety and evaluation of the efficacy in induction of clinical response or remission. Safety will be assessed by recording of adverse events and assessment of changes in clinical laboratory parameters, vital signs and electrocardiogram. Population pharmacokinetics will evaluate the two doses of GSK1605786A. Health outcomes assessments will include changes in Inflammatory Bowel Disease Questionnaire, SF-36, EQ-5D, and Work Productivity and Activity Impairment-Crohn's Disease.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:
Percentage of participants achieving clinical response at Week 12
Timeframe: At Week 12
Secondary outcomes:
Percentage of participants achieving clinical remission at Week 8, Week 12 and at both Week 8 and Week 12
Timeframe: Week 8 and Week 12
Percentage of participants with a clinical response at Week 8 and at both Week 8 and Week 12
Timeframe: Both Week 8 and Week 12
Change from Baseline in C-reactive protein concentration at Weeks 4, 8, and 12
Timeframe: Baseline (Screening) and Weeks 4, 8, and Week 12
Change from Baseline in faecal calprotectin at Week 12
Timeframe: Baseline (Screening) and Week 12
Pharmacokinetics (PK) of GSK1605786A
Timeframe: Baseline (Screening) and Week 12
Pharmacogenetic analyses
Timeframe: Post randomization any time during early two weeks
Interventions:
Enrollment:
255
Primary completion date:
2013-17-10
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
B. G. Feagan, W. Sandborn, G. D’Haens, S. Lee, M. Allez, R. Fedorak, U. Seidler, S. Vermeire, I. Lawrance, A. Maroney, C. H. Jurgensen, A. Heath, D. J. Chang.Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease.Aliment Pharmacol Ther.2015;42(10):1170–1181.
Medical condition
Crohn's Disease
Product
vercirnon
Collaborators
Not applicable
Study date(s)
November 2011 to October 2013
Type
Interventional
Phase
3
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- Male or female subjects aged 18 years or older
- Written informed consent prior to any of the screening procedures including discontinuation of prohibited medications
- Known coeliac disease, those who follow a gluten-free diet to manage symptoms of suspected coeliac disease and subjects with a positive screening test for coeliac disease (elevated anti-tissue transglutaminase antibodies)
- Diagnosis of ulcerative or indeterminate colitis
Inclusion and exclusion criteria
Inclusion criteria:
- Male or female subjects aged 18 years or older -Written informed consent prior to any of the screening procedures including discontinuation of prohibited medications -Diagnosis of Crohn’s disease for more than 4 months with small bowel and/or colonic involvement -Current evidence of moderately-to-severely active disease defined by a baseline Crohn's Disease Activity Index (CDAI) score of 220 to 450, inclusive -Confirmation of active disease by elevated CRP (greater than or equal to the upper limit of normal for the highly sensitive C-reactive protein test) or elevated levels of faecal calprotectin -History of inadequate response and/or intolerance or adverse event leading to discontinuation of at least one of the following treatments for Crohn’s disease: corticosteroids or immunosuppressants -Stable doses of permitted concomitant medications or having previously received, but are not currently receiving, medications for Crohn’s disease -Demonstrated ability to comply with Crohn’s disease symptom recording using the interactive voice response system -Female subjects of child-bearing potential are eligible if not pregnant or nursing and committed to use of contraceptive methods with a failure rate of less than 1 percent per year
Exclusion criteria:
- Known coeliac disease, those who follow a gluten-free diet to manage symptoms of suspected coeliac disease and subjects with a positive screening test for coeliac disease (elevated anti-tissue transglutaminase antibodies) -Diagnosis of ulcerative or indeterminate colitis -Enterocutaneous, abdominal or pelvic fistulae with abscesses, or fistulae likely to require surgery during the course of the study period -Bowel surgery, other than appendectomy, within 12 weeks prior to screening and/or has planned surgery or deemed likely to need surgery for Crohn's disease during the study period -Extensive colonic resection, subtotal or total colectomy -Presence of ileostomies, colostomies or rectal pouches -Fixed symptomatic stenoses of small bowel or colon -History of more than 3 small bowel resections or diagnosis of short bowel syndrome -Chronic use of narcotics for chronic pain defined as daily use of one or more doses of narcotic containing medicaitons -Use of prohibited medications, including enteral feeding or elemental diet, within their specified timeframes and throughout the study. Prohibited medications include the following: a. Biologic use: Use of any TNF inhibitor (such as infliximab, adalimumab or certolizumab) or natalizumab within 10 weeks prior to Randomisation b. Corticosteroid use: Use of parenteral glucocorticoids within 4 weeks prior to Screening c. Immunospressant use: Use of cyclosporine, tacrolimus, sirolimus or mycophenolate mofetil within 4 weeks prior to Screening d. Intravenous antibiotic use: Use of intravenous antibiotics for Crohn’s disease within 4 weeks prior to Screening e. Enteral feeding: Use of tube or enteral feeding, elemental diet within 2 weeks prior to Screening f. Rectal Treatment: Use of 5-aminosalicylates or corticosteroid enemas or suppositories within 2 weeks prior to Screening g. Leukocytapheresis or granulocytapheresis within 2 weeks prior to Screening h. Paracetamol or acetaminophen greater than 2 grams per day i. Opioid analgesics for worsening Crohn’s disease pain are prohibited when used on a regular daily basis for more than 3 days j. Digoxin or related cardiac glycosides: Use within 7 days prior to Screening k. Any previous participation in a clinical study of GSK1605786A (formerly ChemoCentryx compound CCX282-B) -Positive immunoassay for Clostridium difficile -Known HIV infection -Known varicella, herpes zoster, or other severe viral infection within 6 weeks of screening -Immunization with a live vaccine within 4 weeks of Screening and throughout the study with the exception of the influenza vaccine -Positive hepatitis B surface antigen or hepatitis B core antibody test or positive Hepatitis C test result at Screening -Active or latent tuberculosis infection determined by results of QuantiFERON TB Gold test -Current sepsis or infections requiring intravenous antibiotic therapy for more than 2 weeks -Previous infections characterised by opportunistic pathogens, and/or dissemination suggestive of clinically significant immunocompromise -Evidence of hepatic dysfunction, viral hepatitis, or abnormalities in liver function test results -Corrected QT interval of ECG (electrocardiogram) greater than or equal to 450 milliseconds -Congenital or acquired immunodeficiency or has evidence of immunocompromise manifested by current opportunistic infection -Current evidence of, or has been treated for a malignancy within the past five years (other than localised basal cell, squamous cell skin cancer, cervical dysplasia, or any cancer in situ that has been resected) -History of evidence of adenomatous colonic polyps that have not been removed. -History of evidence of colonic mucosal dysplasia -If female, is pregnant, has a positive pregnancy test or is breast-feeding -Concurrent illness or disability that may affect the interpretation of clinical data, or otherwise contraindicates participation in this clinical study (such as an unstable cardiovascular, autoimmune, renal, hepatic, pulmonary, endocrine, metabolic, gastrointestinal, haematologic, or neurological condition or mental impairment) -Medical history of sensitivity to any of the components of GSK1605786A (microcrystalline cellulose, crospovidone, sodium stearyl fumarate). -Use of any investigational product within 30 days prior to screening
Trial location(s)
Showing 1 - 6 of 219 Results
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Other
Actual primary completion date
2013-17-10
Actual study completion date
2013-17-10
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website